28 August 2025 | Thursday | News
Image Source : Public Domain
Avance Clinical, a partner for biotechs providing global contract research organization services, has now guided 710 emerging biotechs through critical clinical trial inflection points.
Avance Clinical’s comprehensive approach to Phase I clinical development has delivered consistent results across the portfolio, bridging studies and first-in-human trials. Most of these programs have successfully advanced to their next milestone, including securing follow-on funding, progressing to Phase II trials, and initiating more pivotal studies.
“Too often biotechs stall, not because of science, but because they are unable to navigate early-phase inflection points efficiently,” said Mark Harvill, CEO, at Avance Clinical. “Much like a start-up benefits from a solid foundation, we’re creating the acceleration for emerging biotechs to help them get to those critical milestones. By accelerating timelines by as much as nine months, we’re advancing their progress and potentially delivering life-changing treatments to patients sooner.”
Those common hurdles which stall early-stage biotechs are largely due to strategic or operational misalignment. Most often, biotechs experience this in:
Avance Clinical addresses these challenges proactively by assessing early data and preparing regulatory submissions up front. This approach ensures clients can anticipate roadblocks, reduce delays, protect capital from the beginning, and overall provide greater confidence to reach their next inflection point.
“These achievements highlight the strategic value of integrating operational excellence with expert regulatory guidance to de-risk early-stage development,” said Ben Edwards, Chief Operating Officer, at Avance Clinical. “This direction allows us to be the accelerator for our clients to ensure a sustained competitive advantage and progression through later stage development.”
Most Read
Bio Jobs
News
Editor Picks